Response to levodopa challenge in Tourette syndrome
Identifieur interne : 002C68 ( Istex/Corpus ); précédent : 002C67; suivant : 002C69Response to levodopa challenge in Tourette syndrome
Auteurs : Kevin J. Black ; Jonathan W. MinkSource :
- Movement Disorders [ 0885-3185 ] ; 2000-11.
English descriptors
- KwdEn :
Abstract
A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.
Url:
DOI: 10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H
Links to Exploration step
ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to levodopa challenge in Tourette syndrome</title><author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name><affiliation><mods:affiliation>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name><affiliation><mods:affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</idno><idno type="url">https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Response to levodopa challenge in Tourette syndrome</title><author><name sortKey="Black, Kevin J" sort="Black, Kevin J" uniqKey="Black K" first="Kevin J." last="Black">Kevin J. Black</name><affiliation><mods:affiliation>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name><affiliation><mods:affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-11">2000-11</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1194">1194</biblScope><biblScope unit="page" to="1198">1198</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A53A348D04CC3B732DB591A0CF668C4F83649089</idno><idno type="DOI">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</idno><idno type="ArticleID">MDS1019</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Levodopa</term><term>Tourette syndrome/treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Kevin J. Black MD</name><affiliations><json:string>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</json:string><json:string>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</json:string><json:string>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</json:string></affiliations></json:item><json:item><name>Jonathan W. Mink MD, PhD</name><affiliations><json:string>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</json:string><json:string>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Tourette syndrome/treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa</value></json:item></subject><language><json:string>eng</json:string></language><abstract>A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p >0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p >0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</abstract><qualityIndicators><score>4.45</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>919</abstractCharCount><pdfWordCount>2830</pdfWordCount><pdfCharCount>17834</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>135</abstractWordCount></qualityIndicators><title>Response to levodopa challenge in Tourette syndrome</title><genre><json:string>Serial article</json:string></genre><host><volume>15</volume><pages><total>5</total><last>1198</last><first>1194</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/1531-8257(200011)15:6>1194::AID-MDS1019>3.0.CO;2-H</json:string></doi><id>A53A348D04CC3B732DB591A0CF668C4F83649089</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Response to levodopa challenge in Tourette syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2000</date></publicationStmt><notesStmt><note>NIH - No. NS01808; No. NS01898;</note><note>National Alliance for Research on Schizophrenia and Depression (NARSAD)</note><note>Tourette Syndrome Association</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Response to levodopa challenge in Tourette syndrome</title><author><persName><forename type="first">Kevin J.</forename><surname>Black</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Campus Box 8225, 4525 Scott Ave., St. Louis, MO 63110, U.S.A.</p></note><affiliation>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation></author><author><persName><forename type="first">Jonathan W.</forename><surname>Mink</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-11"></date><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1194">1194</biblScope><biblScope unit="page" to="1198">1198</biblScope></imprint></monogr><idno type="istex">A53A348D04CC3B732DB591A0CF668C4F83649089</idno><idno type="DOI">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</idno><idno type="ArticleID">MDS1019</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Tourette syndrome/treatment</term></item><item><term>Levodopa</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-12-03">Received</change><change when="2000-06-07">Registration</change><change when="2000-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A53A348D04CC3B732DB591A0CF668C4F83649089/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/1531-8257(200011)15:6<>1.0.CO;2-D</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2000-11">November 2000</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="19" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</doi><idGroup><id type="unit" value="MDS1019"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-12-03"></event><event type="manuscriptRevised" date="2000-06-07"></event><event type="manuscriptAccepted" date="2000-06-07"></event><event type="firstOnline" date="2001-01-17"></event><event type="publishedOnlineFinalForm" date="2001-01-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1194</numbering><numbering type="pageLast">1198</numbering></numberingGroup><correspondenceTo>Campus Box 8225, 4525 Scott Ave., St. Louis, MO 63110, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1019.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="21"></count><count type="wordTotal" number="2751"></count></countGroup><titleGroup><title type="main" xml:lang="en">Response to levodopa challenge in Tourette syndrome</title><title type="short" xml:lang="en">Levodopa Challenge in Tourette Syndrome</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3" corresponding="yes"><personName><givenNames>Kevin J.</givenNames><familyName>Black</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2 #af4"><personName><givenNames>Jonathan W.</givenNames><familyName>Mink</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Tourette syndrome/treatment</keyword><keyword xml:id="kwd2">Levodopa</keyword></keywordGroup><fundingInfo><fundingAgency>NIH</fundingAgency><fundingNumber>NS01808</fundingNumber><fundingNumber>NS01898</fundingNumber></fundingInfo><fundingInfo><fundingAgency>National Alliance for Research on Schizophrenia and Depression (NARSAD)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Tourette Syndrome Association</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Response to levodopa challenge in Tourette syndrome</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levodopa Challenge in Tourette Syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Response to levodopa challenge in Tourette syndrome</title></titleInfo><name type="personal"><namePart type="given">Kevin J.</namePart><namePart type="family">Black</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Department of Radiology, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><description>Correspondence: Campus Box 8225, 4525 Scott Ave., St. Louis, MO 63110, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jonathan W.</namePart><namePart type="family">Mink</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Departments of Neurology and Neurological Surgery, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><affiliation>Departments of Anatomy and Neurobiology, and Pediatrics, Washington University School of Medicine, and the Mallinckrodt Institute of Radiology, St. Louis, Missouri, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2000-11</dateIssued><dateCaptured encoding="w3cdtf">1999-12-03</dateCaptured><dateValid encoding="w3cdtf">2000-06-07</dateValid><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">21</extent><extent unit="words">2751</extent></physicalDescription><abstract lang="en">A dopaminergic excess has been commonly postulated in the pathophysiology of tics, and an early report described acute worsening of tics with levodopa. However, dopamine agonists sometimes improve tics. We undertook this pilot study to determine whether people with tics could tolerate an acute dose of levodopa. Six adults with Tourette syndrome (TS) who had never been treated with neuroleptics took 150 mg levodopa by mouth under single‐blind conditions after carbidopa pretreatment. All six subjects reported a decrease in self‐rated tic severity (mean −40%, p <0.05), and three spontaneously asked if they could be prescribed levodopa for chronic treatment. Blinded videotape ratings of motor tic severity improved by 37% (p <0.02). A large, placebo‐controlled trial will be required to confirm these findings, which raise important questions concerning the relationship of tic expression to dopaminergic activity.</abstract><note type="funding">NIH - No. NS01808; No. NS01898; </note><note type="funding">National Alliance for Research on Schizophrenia and Depression (NARSAD)</note><note type="funding">Tourette Syndrome Association</note><subject lang="en"><genre>Keywords</genre><topic>Tourette syndrome/treatment</topic><topic>Levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1194</start><end>1198</end><total>5</total></extent></part></relatedItem><identifier type="istex">A53A348D04CC3B732DB591A0CF668C4F83649089</identifier><identifier type="DOI">10.1002/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H</identifier><identifier type="ArticleID">MDS1019</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002C68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A53A348D04CC3B732DB591A0CF668C4F83649089
|texte= Response to levodopa challenge in Tourette syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |